Global drug maker Pfizer and biotech firm Amgen, each valued at over HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned. A source said on Monday that these industry leaders were among companies from the fintech, cloud computing and aerial transport sectors set to sign agreements with the Offic...
Global drug maker Pfizer and biotech firm Amgen, each valued at over HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned. A source said on Monday that these industry leaders were among companies from the fintech, cloud computing and aerial transport sectors set to sign agreements with the Office for Attracting Strategic Enterprises. The move will mark the sixth cohort under the government’s...
Getty Images The following segment was excerpted from the Aristotle Capital's Value Equity WM Composite Portfolio Q1 2026 Commentary. Headquartered in Baltimore, Maryland, and founded in 1889, McCormick & Company ( MKC ) is the global leader in spices, seasonings and flavor solutions. With a market capitalization of approximately $18 billion, the company manufactures, markets and distributes a bro...
Getty Images The following segment was excerpted from the Aristotle Capital's Value Equity WM Composite Portfolio Q1 2026 Commentary. Headquartered in Baltimore, Maryland, and founded in 1889, McCormick & Company ( MKC ) is the global leader in spices, seasonings and flavor solutions. With a market capitalization of approximately $18 billion, the company manufactures, markets and distributes a broad portfolio of branded consumer products, as well as customized flavor solutions, to food manufacturers and foodservice customers globally. McCormick operates through two primary segments: Consumer (57%) and Flavor Solutions (43%), serving retail, foodservice and packaged food customers across the Americas, EMEA and Asia Pacific. McCormick has built a long history of consistent growth, strong brand equity and resilient cash generation, supported by commanding market share positions in core categories such as spices and seasonings. Importantly, seasoning is not simply the blending of ingredients; McCormick embeds proprietary flavor technology into its development process, leveraging decades of culinary expertise. The company benefits from scale advantages in sourcing, differentiated capabilities across savory, citrus, sweet and "heat" flavor profiles, and a global innovation and commercialization platform that reinforces its competitive position. More recently, management has articulated a clear strategy to expand operating margins, particularly within its Flavor Solutions segment, while investing behind higher-growth platforms such as its heat portfolio. In addition, the company recently increased its ownership in McCormick de Mexico, consolidating a historically partially-owned business and enhancing its exposure to faster-growing Latin American markets. Under CEO Brendan Foley, McCormick is focused on leveraging its culinary expertise, innovation capabilities and global footprint to drive sustainable earnings growth and long-term value creation. High-Quality Business Som...
kyoshino/E+ via Getty Images No events scheduled More on U.S. Markets S&P 500: I Sold Too Early, What Now? (Technical Analysis) The Trade Driving The S&P 500 Higher May Not Last The Year's Most Positive Signal Rallies Markets, But Iran Risk Favors Select Sectors Markets brace for volatility as Strait of Hormuz tensions return Options traders shift from war fears to chasing tech rally ahead of earn...
kyoshino/E+ via Getty Images No events scheduled More on U.S. Markets S&P 500: I Sold Too Early, What Now? (Technical Analysis) The Trade Driving The S&P 500 Higher May Not Last The Year's Most Positive Signal Rallies Markets, But Iran Risk Favors Select Sectors Markets brace for volatility as Strait of Hormuz tensions return Options traders shift from war fears to chasing tech rally ahead of earnings
(RTTNews) - Nxera Pharma Co., Ltd. (4565.T, SOLTF), a research-based biopharmaceutical company, on Monday announced that it will receive a $10 million milestone payment from AbbVie Inc. (ABBV), a research-based biopharmaceutical company. The payment follows the achievement of a
(RTTNews) - Nxera Pharma Co., Ltd. (4565.T, SOLTF), a research-based biopharmaceutical company, on Monday announced that it will receive a $10 million milestone payment from AbbVie Inc. (ABBV), a research-based biopharmaceutical company. The payment follows the achievement of a